Detection of Hepatic Metastases with low MI Real Time Contrast Enhanced Sonography and SonoVue®

Oldenburg, A.; Hohmann, Joachim; Foert, E.; Skrok, Jan; Hoffmann, C. W.; Frericks, Bernd; Wolf, K. J.; Albrecht, Thomas

doi:10.1055/s-2005-858526

Cited by 67 publications

(56 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In adults, numerous applications have been assessed and reported in the literature-particularly the use of US-CAs for lesion detection and characterisation in abdominal parenchymal organs (predominantly the liver) [32,[41][42][43][44][45][46][47][48][49][50][51][52]. These reports demonstrate not only a high diagnostic potential and reliability of CE-US, but also a high safety profile of US-CAs; in adults, anaphylactoid reactions have been reported at a low rate of less than 0.002% [53,54].…”

Section: Discussionmentioning

confidence: 99%

Application of a second-generation US contrast agent in infants and children—a European questionnaire-based survey

Riccabona

2012

Pediatr Radiol

100

View full text Add to dashboard Cite

Background No US contrast agent (US-CA) is currently licensed for use in children.Objective To survey the off-label use in children of a second-generation US-CA. Materials and methods Questionnaires were e-mailed to European paediatric radiologists, who were asked about their experience with the second-generation US-CA Sonovue® (Bracco, Milan, Italy). Number of examinations per indication and adverse effects were recorded. Examinations were categorised by intravenous or intracavitary use of US-CA. Results Out of 146 respondents, 88 stated that they did not perform contrast-enhanced US in children, but 36 of these (44%) would appreciate paediatric approval. Fortyfive centres reported 5,079 examinations in children (age mean: 2.9 years; range: birth-18 years, M/F: 1/ 2.8). The majority (4,131 [81%] in 29 centres) were intravesical applications. The minority (948 [19%] in 30 centres) were intravenous applications. No adverse effects had been recorded from intravesical use. Six minor adverse effects (skin reaction, unusual taste, hyperventilation) had been recorded after five intravenous studies (0.52%). Conclusion Responses suggest a favourable safety profile of this second-generation US-CA in children. It also demonstrates a demand for such US-CA from paediatric radiologists.

show abstract

Section: Discussionmentioning

confidence: 99%

Application of a second-generation US contrast agent in infants and children—a European questionnaire-based survey

Riccabona

2012

Pediatr Radiol

100

View full text Add to dashboard Cite

show abstract

“…Histologically, metastatic tumors have intratumoral hypo-vascularity and peripheral hyper-vascularity. BUS may miss iso-echoic lesions and lesions smaller than 1 cm [50] . Many studies have confirmed the improvement in accuracy of CEUS in diagnosing MLC [40,51,52] .…”

Section: A B Cmentioning

confidence: 99%

Detection of focal liver lesions in cirrhotic liver using contrast-enhanced ultrasound

Wong

Xu²,

Xie³

2009

WJR

View full text Add to dashboard Cite

Patients with liver cirrhosis are at increased risk of hepatocellular carcinoma (HCC). Conventional or baseline ultrasound (BUS) is often used as the first-line tool for HCC surveillance or detection, but the accuracy of BUS in HCC detection or differentiation from other focal liver lesions (FLLs) is limited. Contrast-enhanced ultrasound (CEUS) represents a recent revolution in the field of ultrasonography and it has become increasingly important in the detection and evaluation of FLLs. In CEUS, HCC typically exhibits arterial hyper-enhancement and portal-venous washout represented by hypoenhanced lesions in the portal venous and late phases. The detection rate of HCC was significantly higher with CEUS compared with BUS. Even regenerative or some dysplastic nodules may exhibit arterial hyperenhancement as they are differentiated from HCC by its iso-enhancing pattern in portal and late phases. The contrast-enhancement patterns of other different types of benign and malignant FLLs, as well as their detection rates with CEUS, were also discussed.

show abstract

“…[12][13][14][15] Contrast-enhanced US (CEUS) has been demonstrated to significantly improve the detection of liver metastases in comparison with B-mode US, including a multicenter trial study. 16 The results are within the same range as for CT. CEUS also can differentiate between most benign and malignant liver lesions by analyzing the portal venous phase in patients with normal liver parenchyma.…”

mentioning

confidence: 99%

Contrast‐enhanced ultrasound of histologically proven liver hemangiomas†

et al. 2007

View full text Add to dashboard Cite

Differentiation of small and atypical hemangiomas from other hepatic masses using imaging methods can be difficult, especially in patients with underlying malignant disease. Therefore, contrast-enhanced ultrasound was assessed in patients with histologically confirmed hemangiomas with respect to contrast-enhancing kinetics and tumor characteristics. In 58 patients with indeterminate hepatic lesions demonstrated with at least 2 imaging methods (ultrasound/computed tomography/magnetic resonance imaging), ultrasound-guided liver biopsy revealed hemangioma. In all patients a hepatic neoplasm had been suspected because of underlying malignant disease (n ‫؍‬ 41), liver cirrhosis (n ‫؍‬ 15), or growth of the lesion (n ‫؍‬ 2). All patients underwent nonlinear, low mechanical index real-time contrast-enhanced ultrasound scanning with bolus injections of SonoVue. Peripheral nodular arterial enhancement was detected in 43 patients (74%), whereas the typical metastatic peripheral rim-like enhancement was not observed at all. Strong homogenous arterial enhancement was found in 9 of 58 (16%) patients. In 6 patients (10%), the arterial contrast enhancement pattern could not be determined because of the very small size of the lesions or fibrotic nodules. Forty-five (78%) of the hemangiomas showed homogenous centripetal filling within 180 seconds. Conclusion: Contrast-enhanced ultrasound demonstrates typical hemangioma imaging characteristics, that is, peripheral nodular contrast enhancement and iris-diaphragm sign in a high percentage of patients with undetermined lesions. This technique may therefore improve noninvasive functional characterization and differentiation of hemangiomas. (HEPATOLOGY 2007;45:1139-1145

show abstract

Detection of Hepatic Metastases with low MI Real Time Contrast Enhanced Sonography and SonoVue®

Abstract: Detection of hepatic metastases is substantially improved by low MI real time contrast enhanced ultrasound with SonoVue compared to conventional B-mode sonography.

Cited by 67 publications

References 8 publications

Application of a second-generation US contrast agent in infants and children—a European questionnaire-based survey

Application of a second-generation US contrast agent in infants and children—a European questionnaire-based survey

Detection of focal liver lesions in cirrhotic liver using contrast-enhanced ultrasound

Contrast‐enhanced ultrasound of histologically proven liver hemangiomas†

Contact Info

Product

Resources

About